Aspen Pharmacare Holdings Limited (APN) Earnings Call Transcripts

Aspen Pharmacare Holdings Limited's Latest Earnings Call - May 29, 2026

In the earnings call for the quarter ending May 29, 2026, Aspen Pharmacare Holdings Limited announced the successful completion of the divestment of its Asia Pacific business, which generated gross proceeds of ZAR 28 billion, significantly exceeding prior estimates. This transaction is expected to enhance the company's balance sheet and financial flexibility, with management indicating a strong focus on organic growth and potential share buybacks. The company aims to recover from the loss of revenue due to the divestment and the mRNA contract, targeting a return to ZAR 9.6 billion in adjusted EBITDA by 2027.

Reported metrics

Guidance from management

Management is targeting a return to ZAR 9.6 billion in adjusted EBITDA by FY27, emphasizing the need for significant organic growth to offset recent divestments. No changes to prior guidance were noted.

What management said

Good afternoon, and welcome. Thank you for joining today's live webcast, where we will discuss the completion of the divestment of Aspen APAC. The transaction that was announced late last year. Mr. Stephen Saad will begin with some remarks on the transaction, after which we will open the floor to questions specifically relating to the transaction, both Stephen and Sean Capazorio are available to answer your questions...

Thank you very much, Stephen. I think everybody has been listening quite intently. [Operator Instructions] Stephen, if we can just give it 30 seconds, there's no questions that are on line at the moment. So it's obviously pretty clear. But let's just give it 30 seconds and see if they come through.

What analysts pressed on

Analysts raised questions about the company's capital allocation strategy, particularly regarding the potential for share buybacks and how the company plans to achieve its ambitious growth targets in light of recent divestments. There is concern over the execution risks associated with restoring profitability in loss-making facilities.

Main topics on the call

• Completion of APAC Divestment — Aspen successfully completed the divestment of its Asia Pacific business, achieving gross proceeds of ZAR 28 billion, which is higher than the previously communicated ZAR 26 billion. Management stated, 'the value from th...
• Strengthened Balance Sheet — The divestment has significantly strengthened Aspen's balance sheet, with management indicating they are 'very close to a net cash position today.' This marks a pivotal moment for the company, enhancing financial flexibi...
• Future Organic Growth Targets — Management outlined a goal to return to ZAR 9.6 billion in adjusted EBITDA by 2027, necessitating a 60% growth in the base business. This ambitious target is driven by strong growth opportunities in emerging markets and ...
• GLP-1 Product Expansion — Aspen is well-positioned in the GLP-1 market, with successful launches in South Africa and plans to expand into Nigeria and Kenya. Management noted, 'we look well positioned there as well,' highlighting the growth potent...

Read the full Aspen Pharmacare Holdings Limited transcript (May 29, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 21 Aspen Pharmacare Holdings Limited earnings call transcripts on record, spanning March 6, 2020 to May 29, 2026. Based on this history, Aspen Pharmacare Holdings Limited reports quarterly. The most recent call on file is dated May 29, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

APN

Exchange

JSE

Country

ZA

Sector

Health Care

Industry

Pharmaceuticals

Calls on record

21

First call

March 6, 2020

Most recent

May 29, 2026

Reporting cadence

quarterly